Doxorubicin is indicated for treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen.
For this indication, competent medicine agencies globally authorize below treatments:
Intravenous
50 - 50 mg per m² of body surface area (BSA)
From 50 To 50 mg per m² of body surface area (BSA) once every 28 day(s)
Doxorubicin is administered intravenously at a dose of 50 mg/m² once every 4 weeks for as long as the disease does not progress and the patient continues to tolerate treatment.
To minimise the risk of infusion reactions, the initial dose is administered at a rate no greater than 1 mg/minute. If no infusion reaction is observed, subsequent doxorubicin infusions may be administered over a 60-minute period.